EARN25

Axsome Therapeutics Stock Surges on FDA Update

Year-over-year, AXSM remains down 55%

Digital Content Manager
Jun 27, 2022 at 10:49 AM
facebook X logo linkedin


Axsome Therapeutics Inc (NASDAQ:AXSM) is surging today, after the company said it has received proposed labeling from the Food and Drug Administration (FDA) for AXS-05, its drug candidate to treat major depressive disorder. The treatment currently has a marketing application under review. At last check, the security is up 45.1% to trade at $35.48. 
 

The brokerage bunch is yet to chime in, but is already optimistic on AXSM, with eight of the 10 in coverage calling it a "strong buy." Plus, the 12-month consensus target price of $78 is a 131.4% premium to current levels. Meanwhile, short interest is up 10.3% in the last two reporting periods, and accounts for 16.1% of the stock's available float. Should some of this pessimism begin to unwind, shares could surge higher still.

Additional tailwinds could come from a shift in the options pits. Over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), AXSM sports a 50-day put/call volume ratio of 1.55 that sits higher than 93% of readings from the last 12 months. This means long puts are getting picked up at a much quicker-than-usual clip.

Drilling down to today's options activity, 6,852 and 3,014 calls have crossed the tape, which is nine times the intraday average. Most popular is the July 30 call, followed by the 12.50 put in the same series.

The equity is today trading at its highest level since May, while looking to settle above resistance from the 30-day moving average. Today's pop follows a pullback to the $20 region -- its lowest level since August -- though year-over-year AXSM remains down 55%. 

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!